188 related articles for article (PubMed ID: 35863822)
1. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
Carlisle JW; Jansen CS; Cardenas MA; Sobierajska E; Reyes AM; Greenwald R; Del Balzo L; Prokhnevska N; Kucuk O; Carthon BC; Mullane PC; Osunkoya A; Baumgarten D; Hosseinzadeh F; Wilkinson S; Lake R; Sowalsky AG; Liu Y; Master VA; Bilen MA; Kissick H
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863822
[TBL] [Abstract][Full Text] [Related]
2. Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.
Menard LC; Fischer P; Kakrecha B; Linsley PS; Wambre E; Liu MC; Rust BJ; Lee D; Penhallow B; Manjarrez Orduno N; Nadler SG
Front Immunol; 2018; 9():2728. PubMed ID: 30534127
[TBL] [Abstract][Full Text] [Related]
3. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH
J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449
[TBL] [Abstract][Full Text] [Related]
5. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
6. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
8. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
9. Functional Change of Effector Tumor-Infiltrating CCR5
Chen PY; Wu CY; Fang JH; Chen HC; Feng LY; Huang CY; Wei KC; Fang JY; Lin CY
Front Immunol; 2019; 10():2395. PubMed ID: 31649684
[TBL] [Abstract][Full Text] [Related]
10. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers.
Maes M; Bosmans E; Kubera M
Neuro Endocrinol Lett; 2015; 36(5):439-46. PubMed ID: 26707044
[TBL] [Abstract][Full Text] [Related]
12. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
13. Immune expression in children with Wilms tumor: a pilot study.
Holl EK; Routh JC; Johnston AW; Frazier V; Rice HE; Tracy ET; Nair SK
J Pediatr Urol; 2019 Oct; 15(5):441.e1-441.e8. PubMed ID: 30981637
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
16. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
17. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
18. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes.
Mahalingam M; Pozniak A; McManus TJ; Vergani D; Peakman M
Clin Exp Immunol; 1995 Dec; 102(3):481-6. PubMed ID: 8536361
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
20. Innate-like bystander-activated CD38
Huang CH; Fan JH; Jeng WJ; Chang ST; Yang CK; Teng W; Wu TH; Hsieh YC; Chen WT; Chen YC; Sheen IS; Lin YC; Lin CY
Hepatology; 2022 Sep; 76(3):803-818. PubMed ID: 35060158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
